References
- Bruner JM, Tien RD, Enterline DS. Tumors of the meninges and related tissues, in: Bigner DD, McLendon RE, Bruner JM, eds, Russell & Rubinstein's Pathology of Tumors of the Nervous System, 6th edn. Arnold Press, London 1998:67–139.
- Longstreth WT, Dennis LK, McGuire VM, Drangsholt MT, Koepsell TD. Epidemiology of intracranial meningioma. Cancer 1993;72:639–48.
- Akeyson EW, McCutcheon IE. Management of benign and aggressive intracranial meningiomas. Oncology 1996;10:747 — 56.
- Miralbell R, Linggood RM, de al Monte S, et al. The role of radiotherapy in the treatment of subtotally resected benign meningiomas. 3 Neuro-Oncol 1992;13:157–64.
- Stafford SL, Pollock BE, Foote RL, et al. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery 2001;49:1029 — 38.
- Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. 3 Neurosurg 1991;74:861 —6.
- Grunberg SM, Rankin C, Townsend J, et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. Proc ASCO 2001;20:56a.
- Schrell UMH, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. I Neurosurg 1997;86:845–52.
- Newton HB, Slivka MA, Stevens C. Hydroxyurea chemother-apy for unresectable or residual meningiomas. 3 Neurooncol 2000;49: 165–70.
- Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. 3 Clin Oncol 1990;8:1277–80.
- National Cancer Institute. Common Toxicity Criteria. Bethes-da: NCI, 1998.
- Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningeal tumours, in: Kleihues P, Cavanee WK, eds Pathology and genetics. Tumours of the nervous system. IARC Press, Lyon 2000:176–84.
- Mason WP, Gentill F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. I Neurosurg 2002;97:341 —6.
- Newton HB, Turowski RC, Stroup TJ, McCoy LK. Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother 1999;33:816–32.
- Martin DS, Stolfi RL, Colofiore JR. Prespective: the che-motherapeutic relevance of apoptosis and a proposed bio-chemical cascade for chemotherapeutically induced apoptosis. Cancer Investig 1997;15:372–81.